Low
₹
High
₹
| Previous Close | ₹89.35 |
|---|---|
| Day's Range | ₹86.23 - ₹89.95 |
| Open | ₹87.50 |
| 52 Week Range | ₹61.00 - ₹92.90 |
| Volume | 85,836 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 76.69 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 38.56 |
| TTM EPS (₹) | 2.25 |
| P/E Ratio | 46.73 |
| Book Value(₹) | 7.21 |
| PAT Margin (%) | 9.25 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 18.01 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 613.64 | 1771.75 |
| Expenses | N/A | N/A |
| PBT | 100.48 | 405.58 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 75.14 | 303.79 |
| Founded | 1982 |
|---|---|
| Managing Director | S Manivannan |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,972.94 | 1,831.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,025.88 | 6,681.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,477.60 | 4,351.60 | 3,101.60 - 3,101.60 |
| Lupin Ltd. | 1,11,668.12 | 2,460.50 | 1,836.80 - 1,836.80 |
| Apollo Hospitals Enterprise Ltd. | 1,11,526.57 | 7,820.45 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,10,282.52 | 1,361.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,381.80 | 1,307.00 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,852.37 | 1,015.10 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 97,505.92 | 2,375.40 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,495.43 | 940.10 | 835.50 - 835.50 |
No Records Found
Pursuant to the provisions of SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 dated August 10, 2021 (updated as on April 13, 2022) read with the SEBI Circular No. SEBI/HO/DDHS/DDHSRACPOD1/P/CIR/2023/172 dated October 19, 2023 (the said circulars), KMC Speciality Hospitals (India) has confirmed that the Company does not fall under 'Large Corporate' criteria as on March 31, 2026 as per the applicability framework provided in the said circulars. Hence, the disclosure requirements mentioned in the said circulars are not applicable to the Company for the financial year ended on March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
In terms of Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Venmax Drugs and Pharmaceuticals has informed that the Meeting of the Board of Directors is scheduled to be held on Thursday, May 14, 2026 at 3.30 pm to consider and approve, the Audited Financial Results of the Company for the Quarter and Year ended March 31, 2026. Further, the Trading Window for dealing in Securities of the Company which stands closed for all the Designated Persons of the Company with effect from April 1, 2026 would continue to remain closed till May 16, 2026 i.e., till 48 hours after the approval of the Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of KMC Speciality Hospitals (India) Ltd. is ₹89.35 as of 2026-05-07.
The market capitalisation of KMC Speciality Hospitals (India) Ltd. is ₹1,412.15 as of 2026-05-06.
The 1-year return of KMC Speciality Hospitals (India) Ltd. is 21.73% as of 2025-05-06.
The P/E ratio of KMC Speciality Hospitals (India) Ltd. is 46.73 as of 2026-05-07.
The 52-week high and low of KMC Speciality Hospitals (India) Ltd. are ₹92.90 and ₹61.00, respectively, as of 2026-05-07.
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.